Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
With a market cap of 823.32B, Eli Lilly(LLY) trades at $871.14. The stock has a price-to-earnings ratio of 37.83 and currently yields dividends of 71.8%.
During the trading session on 2026-04-28, Eli Lilly(LLY) shares reached a daily high of $878.00 and a low of $870.00. At a current price of $871.14, the stock is +0.1% higher than the low and still -0.8% under the high.
Trading volume for Eli Lilly(LLY) stock has reached 904.6K, versus its average volume of 3.06M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
LLY News
(RTTNews) - Profluent, an AI-first protein design company, on Tuesday announced a multi-program partnership with Eli Lilly and Company worth up ?to $2.25 billio...
Key Points Eli Lilly is best known for its work in the weight loss market. The company has billion-dollar drugs in other areas. The drugmaker continues to ex...
Eli Lilly (NYSE:LLY) agreed to acquire Ajax Therapeutics in a $2.3b transaction, its second oncology deal this month. The acquisition adds AJ1-11095, a clinica...
Analyst ratings
82%
of 34 ratingsMore LLY News
Pharmaceutical giant Eli Lilly (LLY) remains on a buying spree, announcing that it is acquiring cancer drug developer Ajax Therapeutics for $2.3 billion in cash...
Biotech and Pharma As Investors Focus on Lilly’s Foundayo, They May Be Overlooking Another Key Catalyst In this article LLY NVO Eli Lilly is exploring a combina...
Eli Lilly said Ajax is developing next-generation Janus kinase, or JAK, inhibitors for patients with myeloproliferative neoplasms. Mike Blake / Reuters Eli Lil...
Eli Lilly shares slid nearly 4% Friday after early data on prescription volume for its new weight loss pill signaled it’s off to a slow start. Lilly began sell...
Technology Battle Of The Weight-Loss Pills Continues With A Shocking Twist Licensing Eli Lilly (LLY) stock skidded early Friday as Novo Nordisk's (NVO) Wegovy p...
The stock of Hims & Hers Health (HIMS) was up as much as 7% on April 23 after the company announced that it has expanded its partnership with Eli Lilly (LLY)....
Biotech and Pharma Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing. In this article LLY NVO SPX Eli Lilly is the mak...
